首页> 外文OA文献 >EFFICACY AND SAFETY OF ANTI-PD-L1 ANTIBODY IN NSCLC PATIENTS WHO PREVIOUSLY TREATED WITH ANTI PD-1 ANTIBODIES: PRELIMINARY STUDY

【2h】

EFFICACY AND SAFETY OF ANTI-PD-L1 ANTIBODY IN NSCLC PATIENTS WHO PREVIOUSLY TREATED WITH ANTI PD-1 ANTIBODIES: PRELIMINARY STUDY

机译：抗PD-1抗体的NSCLC患者抗PD-L1抗体的疗效和安全性：初步研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. EFFICACY AND SAFETY OF ANTI-PD-L1 ANTIBODY IN NSCLC PATIENTS WHO PREVIOUSLY TREATED WITH ANTI PD-1 ANTIBODIES: PRELIMINARY STUDY [J] . Fujita Kohei, Uchida Naohiro, Yamamoto Yuki, Respirology : . 2018,第Suppla2期

机译：抗PD-1抗体的NSCLC患者抗PD-L1抗体的功效和安全性：初步研究
2. 339?Preliminary safety, tolerability and efficacy results of KN026 (a HER2-targeted Bispecific Antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 Bispecific Antibody) in patients (pts) with HER2 aberrated solid tumors [J] . Jifang Gong, Zhi Dong, Dan Liu, Journal for ImmunoTherapy of Cancer . 2020,第Suppla3期

机译：339？KN026（HER2-靶向双特异性抗体）与KN046（抗PD-L1 / CTLA-4双特异性抗体组合）的初步安全性，耐受性和功效结果，患者（PTS）与HER2似象肿瘤
3. Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis [J] . Minghan Jia, Weijiao Feng, Shiyang Kang, Journal of Thoracic Disease . 2015,第3期

机译：抗PD-1和抗PD-L1抗体在非小细胞肺癌（NSCLC）治疗中的疗效和安全性评估：一项荟萃分析
4. ~(177)Lu-DOTA-J591 MONOCLONAL ANTIBODY: CHEMISTRY, TOXICITY, DOSIMETRY AND CLINICAL EFFICACY: RIT OF PROSTATE CANCER USING ~(177)LU-J591 ANTI-PSMA ANTIBODY [C] . S.J. GOLDSMITH, S. VALLABHAJOSULA, M.I. MILOWSKY, Trends in Radiopharmaceuticals(ISTR-2005) . 2007

机译：〜（177）Lu-DOTA-J591单克隆抗体：化学，毒性，剂量和临床疗效：使用〜（177）LU-J591抗-PSMA抗体的前列腺癌
5. Characterization of Anti-Ricin Monoclonal Antibodies and the Construction of a Chimeric Murine-Human IgG2/K Anti-Ricin Monoclonal Antibody [D] . Vendramelli, Robert Matthew 2011

机译：抗蓖麻毒蛋白单克隆抗体的表征和鼠/人IgG2 / K嵌合抗蓖麻毒蛋白单克隆抗体的构建
6. Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis [O] . Minghan Jia, Weijiao Feng, Shiyang Kang, 2015

机译：抗PD-1和抗PD-L1抗体在非小细胞肺癌（NSCLC）治疗中的疗效和安全性评估：一项荟萃分析
7. 1084P Cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma (mCSCC): Preliminary safety and efficacy results from a phase I clinical trial [O] . P. Clingan, D. Brungs, R. Ladwa, 2020

机译：1084p Cosibelimab，一种抗PD-L1抗体，转移皮肤鳞状细胞癌（MCSCC）：I临床试验中的初步安全性和疗效结果

EFFICACY AND SAFETY OF ANTI-PD-L1 ANTIBODY IN NSCLC PATIENTS WHO PREVIOUSLY TREATED WITH ANTI PD-1 ANTIBODIES: PRELIMINARY STUDY

著录项

引文网络

相似文献

相关主题

期刊订阅